Interestingly, the density of the intratumoral CD3+CD8− T-cells was lower in the responders, suggesting that the combination of Coxsackievirus A21 (V937) and pembrolizumab might help overcome the limitations of a nonimmunologically “active” tumor environment [27]. This evidence concerns the gene CD8A and neoplasm.